Metronidazole gel versus placebo gel — Competitive Intelligence Brief

Metronidazole gel versus placebo gel (Metronidazole gel versus placebo gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antibiotic. Area: Infectious Disease / Dermatology.

phase 3 Nitroimidazole antibiotic Bacterial DNA (via reactive oxygen species generation) Infectious Disease / Dermatology Small molecule

Target snapshot

Metronidazole gel versus placebo gel (Metronidazole gel versus placebo gel) — Johns Hopkins Bloomberg School of Public Health. Metronidazole is a nitroimidazole antibiotic that disrupts bacterial DNA by generating reactive oxygen species, killing anaerobic bacteria and certain protozoa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole gel versus placebo gel TARGET	Metronidazole gel versus placebo gel	Johns Hopkins Bloomberg School of Public Health	phase 3	Nitroimidazole antibiotic	Bacterial DNA (via reactive oxygen species generation)
Metronidazole (BQ10)	Metronidazole (BQ10)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Cefazolin and Metronidazole.	Cefazolin and Metronidazole.	The University of Texas Health Science Center, Houston	marketed	Beta-lactam antibiotic and nitroimidazole antibiotic combination	Penicillin-binding proteins (cefazolin); anaerobic bacterial DNA (metronidazole)
Metronidazole Suppositories	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA
Metronidazole (Metrogel)	Metronidazole (Metrogel)	LEO Pharma	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole Tablet	Metronidazole Tablet	Appili Therapeutics Inc.	marketed	Nitroimidazole antibiotic	Bacterial and parasitic DNA
Metronidazole (ST14)	Metronidazole (ST14)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antibiotic class)

1. National Taiwan University Hospital · 2 drugs in this class
2. Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · 2 drugs in this class
3. University of Guarulhos · 2 drugs in this class
4. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
5. LEO Pharma · 1 drug in this class
6. Sherief Abd-Elsalam · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. Appili Therapeutics Inc. · 1 drug in this class
10. bioRASI, LLC · 1 drug in this class